Metastatik Pankreas Kanserlerinde Cerrahinin Yeri
Özet
Pankreas adenokarsinomu, sıklıkla ileri evrede teşhis edilmesi ve metastatik doğası nedeniyle dünya genelinde yüksek mortalite oranlarına sahip ölümcül bir sindirim sistemi malignitesidir. Evre IV hastalar genel olarak primer tümör rezeksiyonu için aday kabul edilmeseler de, seçilmiş hasta gruplarında yaşam kalitesini artırmak ve sağkalım avantajı sağlamak amacıyla palyatif ve istisnai cerrahi girişimler uygulanabilmektedir. Tümörün baş kısmındaki yerleşimine bağlı olarak gelişen safra yolları ve gastrik çıkış tıkanıklıklarında, endoskopik stentlemenin yetersiz kaldığı veya uygulanamadığı durumlarda biliyoenterik bypass ve gastrojejunostomi gibi cerrahi prosedürler efektif bir palyasyon sağlamaktadır. Bunun yanı sıra, primer pankreas kitlesi tamamen rezeke edilebilir olan ve ek sistemik yayılımı bulunmayan uygun olgularda, izole karaciğer veya akciğer metastazektomilerinin (senkron veya metakron) genel sağkalım sürelerini belirgin şekilde artırabildiği güncel klinik çalışmalarla ortaya konmuştur. Sonuç olarak, metastatik hastalıkta ana tedavi unsuru sistemik kemoterapi olmaya devam etse de, uzmanlaşmış merkezlerde multidisipliner yaklaşımla gerçekleştirilen hasta bazlı cerrahi değerlendirmeler ve komplikasyonlara yönelik zamanında müdahaleler, hastaların yaşam konforunu optimize etmede ve sağkalımı uzatmada kritik bir rol oynamaktadır.
Pancreatic adenocarcinoma is a highly lethal gastrointestinal malignancy frequently diagnosed at an advanced or metastatic stage, which inherently accounts for its low overall survival rates globally. Although Stage IV patients are generally excluded from primary tumor resection protocols, palliative and exceptional surgical interventions can be successfully performed in highly selected cohorts to substantially enhance quality of life and provide survival benefits. In cases of biliary and gastric outlet obstructions induced by tumors located in the pancreatic head, surgical alternatives such as bilioenteric bypass and gastrojejunostomy offer highly effective symptomatic relief when endoscopic stenting fails or is contraindicated. Furthermore, contemporary clinical studies demonstrate that synchronous or metachronous metastasectomy for isolated liver or lung metastases can significantly prolong overall survival, provided that the primary pancreatic mass is completely resectable and no further extrahepatic dissemination is present. Consequently, while systemic chemotherapy remains the cornerstone management for metastatic disease, personalized surgical evaluations and strategic interventions for tumor-related complications in high-volume specialized centers play a vital role in extending patient longevity and optimizing their general well-being.
Referanslar
International Agency for Research on Cancer, World Health Organization (2020). Global Cancer Observatory 2020. (15/11/2021 tarihinde https://gco.iarc.fr/today adresinden ulaşılmıştır).
McGuigan A, Kelly P, Turkington RC et. al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-4861. doi:10.3748/wjg.v24.i43.4846
Poruk KE, Wolfgang CL. Palliative Management of Unresectable Pancreas Cancer. Surg Oncol Clin N Am. 2016 Apr;25(2):327-37. doi: 10.1016/j.soc.2015.11.005
Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91(5):586–94.
Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10(9):1199–210 [discussion: 1210–1].
Akgül Ö, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014 May 28;20(20):6113-22. doi: 10.3748/wjg.v20.i20.6113
Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020 Jan-Dec;27(1):1073274820976593. doi: 10.1177/1073274820976593.
Arnaoutakis GJ, Rangachari D, Laheru DA, et. al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011 Sep;15(9):1611-7. doi: 10.1007/s11605-011-1605-8.
House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am. 2005 Apr;85(2):359-71. doi: 10.1016/j.suc.2005.01.022.
Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc. 2006 Jun;63(7):986-95. doi: 10.1016/j.gie.2005.11.052.
Sohn TA, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 1999;188(6):658–66 [discussion: 666–9].
Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD004200. doi: 10.1002/14651858.CD004200.pub4.
Kitano M, Yamashita Y, Tanaka K, et. al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013 Nov;108(11):1713-22. doi: 10.1038/ajg.2013.305.
Thor PJ, Popiela T, Sobocki J, et al. Pancreatic carcinoma-induced changes ingastric myoelectric activity and emptying. Hepatogastroenterology 2002;49(43):268–70.
Maire F, Hammel P, Ponsot P et. al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol. 2006 Apr;101(4):735-42. doi: 10.1111/j.1572-0241.2006.00559.x.
Scott EN, Garcea G, Doucas H, et al. Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma. HPB (Oxford) 2009;11(2):118–24.
Lillemoe KD, Cameron JL, Hardacre JM et. al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999 Sep;230(3):322-8; discussion 328-30. doi: 10.1097/00000658-199909000-00005.
Van Heek NT, De Castro SM, van Eijck CH et. al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg. 2003 Dec;238(6):894-902; discussion 902-5. doi: 10.1097/01.sla.0000098617.21801.95.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
van der Geest LGM, Lemmens V, de Hingh I, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017;104(11):1568–1577.
Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020 Jan-Dec;27(1):1073274820976593. doi: 10.1177/1073274820976593.
Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(2):358–363.
Andreou A, Knitter S, Klein F, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27(4):688–694
Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136–144.
Yang J, Zhang J, Lui W, et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford). 2020;22(1):91–101.
Bahra M, Pratschke J, Klein F, et al. Cytoreductive surgery for pancreatic cancer improves overall outcome of gemcitabine-based chemotherapy. Pancreas. 2015;44(6):930–936.
Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: diagnosis and assessment of unresectability. World J Gastroenterol. 2016;22(45):10024–10037.
Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14(1):118–127.
Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20(11):1830–1835.
Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–2492.
Klein F, Puhl G, Guckelberger O, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012;2012:939350.
de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102(3):256–263.
Zanini N, Lombardi R, Masetti M, et. al. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 2015;67(1):19–25.
Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42(10):1533–1539
Takada T, Yasuda H, Amano H, et. al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology. 1997;44(14):567–573.
Yamada H, Hirano S, Tanaka E et. al. Surgical treatment of liver metastases from pancreatic cancer. HPB (Oxford). 2006;8(2):85–88.
Katz MH, Wang H, Fleming JB, et. al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr;16(4):836-47. doi: 10.1245/s10434-008-0295-2.
Liu, Q., Zhang, R., Michalski, C.W. et al. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Sci Rep 10, 4444 (2020). https://doi.org/10.1038/s41598-020-61487-0
